Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats

BMC Pharmacology and Toxicology

Volumn 14, Issue , 2013, Pages

  Gowda, Nagesh ^a   Dandu, Anilkumar ^a   Singh, Jaideep ^a   Biswas, Sanghamitra ^a   Raghav, Vijaya ^a   Lakshmi, Mudigere N ^a   Shilpa, Pavagada C ^a   Sunil, Venkategowda ^a   Reddy, Ashokkumar ^a   Sadasivuni, Manojkumar ^a   Aparna, Kumaraswamy ^a   Verma, Mahesh Kumar ^a   Moolemath, Yoganand ^a   Anup, Mammen O ^a   Venkataranganna, Marikunte V ^a   Somesh, Baggavalli P ^a   Jagannath, Madanahalli R ^a  

^a Connexios Life Sciences Pvt Ltd ^*  (India)

Author keywords

Glucolipotoxicity; GPR40; GSIS; Insulin content; PDX1; Rat islets; Type 2 diabetes; Zucker diabetic fatty rats

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIDIABETIC AGENT; CNX 01167; FATTY ACID; FRUCTOSAMINE; G PROTEIN COUPLED RECEPTOR 40; GLUCOSE; HEMOGLOBIN A1C; INSULIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CARRIER PROTEIN; CNX-011-67; DDIT3 PROTEIN, RAT; DRUG; G PROTEIN COUPLED RECEPTOR; G-PROTEIN-COUPLED RECEPTOR 40, RAT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HOMEODOMAIN PROTEIN; PANCREATIC AND DUODENAL HOMEOBOX 1 PROTEIN; TRANSACTIVATOR PROTEIN; TXNIP PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE COURSE; ELECTRON MICROSCOPY; ERYTHROCYTE PRESERVATION; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; INSULIN TOLERANCE TEST; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS; PANCREAS ISLET BETA CELL; RAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; AGONISTS; ANIMAL; BLOOD; CHO CELL LINE; CRICETULUS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HAMSTER; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; ULTRASTRUCTURE; ZUCKER RAT;

ANIMALS; BLOOD GLUCOSE; CARRIER PROTEINS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, NONESTERIFIED; FRUCTOSAMINE; GENE EXPRESSION; HEMOGLOBIN A, GLYCOSYLATED; HOMEODOMAIN PROTEINS; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN-SECRETING CELLS; MALE; PHARMACEUTICAL PREPARATIONS; RATS, ZUCKER; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTOR CHOP; TRIGLYCERIDES;

EID: 84880637351     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-14-28     Document Type: Article

References (40)

1. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012, 14:675-688. 10.1111/j.1463-1326.2012.01560.x, 22233527.
2. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006, 18. CD006060.
3. Sreenan S, Sturis J, Pugh W, Burant CF, Polonsky KS. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol 1996, 271:742-747.
4. Briscoe CP, Peat AJ, McKeown SC, Corbett DF, Goetz AS, Littleton TR, McCoy DC, Kenakin TP, Andrews JL, Ammala C, Fornwald JA, Ignar DM, Jenkinson S. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 2009, 148:619-628.
5. Shapiro H, Shachar S, Sekler I, Hershfinkel M, Walker MD. Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem Biophys Res Commun 2005, 335:97-104. 10.1016/j.bbrc.2005.07.042, 16081037.
6. Fujiwara K, Maekawa F, Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab 2005, 289:670-677.
7. Tan CP, Feng Y, Zhou YP, Eiermann GJ, Petrov A, Zhou C, Lin S, Salituro G, Meinke P, Mosley R, Akiyama TE, Einstein M, Kumar S, Berger JP, Mills SG, Thornberry NA, Yang L, Howard AD. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008, 57:2211-2219. 10.2337/db08-0130, 2494688, 18477808.
8. Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, Momose Y, Takeuchi K. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 2011, 339:228-327. 10.1124/jpet.111.183772, 21752941.
9. Lin DC, Zhang J, Zhuang R, Li F, Nguyen K, Chen M, Tran T, Lopez E, Lu JY, Li XN, Tang L, Tonn GR, Swaminath G, Reagan JD, Chen JL, Tian H, Lin YJ, Houze JB, Luo J. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One 2011, 6:e27270. 10.1371/journal.pone.0027270, 3210765, 22087278.
10. Luo J, Swaminath G, Brown SP, Zhang J, Guo Q, Chen M, Nguyen K, Tran T, Miao L, Dransfield PJ, Vimolratana M, Houze JB, Wong S, Toteva M, Shan B, Li F, Zhuang R, Lin DC. A Potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One 2012, 7:e46300. 10.1371/journal.pone.0046300, 3467217, 23056280.
11. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, Leifke E. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012, 379:1403-1411. 10.1016/S0140-6736(11)61879-5, 22374408.
12. Kaku K, Araki T, Yoshinaka R. Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes. Diabetes Care 2013, 36:245-250. 10.2337/dc12-0872, 23086138.
13. Tokuyama Y, Sturis J, DePaoli AM, Takeda J, Stoffel M, Tang J, Sun X, Polonsky KS, Bell GI. Evolution of beta cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 1995, 44:1447-1457. 10.2337/diabetes.44.12.1447, 7589853.
14. Yuen VG, Vera E, Battell ML, Li WM, McNeill JH. Acute and chronic oral administration of bis(maltolato) oxovanadium (IV) in Zucker diabetic fatty (ZDF) rats. Diabetes Res Clin Pract 1999, 43:9-19. 10.1016/S0168-8227(98)00120-X, 10199584.
15. Carter JD, Dula SB, Corbin KL, Wu R, Nunemaker CS. A practical guide to rodent islet isolation and assessment. Biol Proced Online 2009, 11:3-31. 10.1007/s12575-009-9021-0, 3056052, 19957062.
16. Luna L. AFIP Manual of Histological Staining Methods 1968, New York: McGraw Hill.
17. Culling CFA, Allison RT, Bair WT. Cellular pathology technique 1985, London: Butterworths.
18. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257. 10.1038/bjc.1972.33, 2008650, 4561027.
19. Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980, 68:251-306.
20. Garrity MM, Burgart LJ, Riehle DL, Hill EM, Sebo TJ, Witzig T. Identifying and Quantifying Apoptosis: Navigating Technical Pitfalls. Mod Pathol 2003, 16:389-394. 10.1097/01.MP.0000062657.30170.92, 12692204.
21. Bruin JE, Gerstein HC, Morrison KM, Holloway AC. Increased pancreatic beta cell apoptosis following fetal and neonatal exposure to nicotine is mediated via the mitochondria. Toxicol Sci 2008, 103:362-370. 10.1093/toxsci/kfn012, 18203686.
22. Watari N, Tsukagoshi N, Honma Y. The correlative light and electron microscopy of the islets of Langerhans in some lower vertebrates. Arch Histol 1970, 31:371-392.
23. Mihail N, Craciun C. An ultrastructural description of the cell types in the endocrine pancreas of the pigeon. Anat Anz Jena 1982, 152:229-237.
24. Misawa E, Tanaka M, Nomaguchi K, Nomaguchia K, Yamada M, Toida T, Takase M, Iwatsuki K, Kawada T. Administration of phytosterols isolated from aloe vera gel reduce visceral fat mass and improve hyperglycemia in Zucker diabetic fatty (zdf) rats. Obes Res Clin Pract 2008, 2:239-245.
25. Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 2003, 46:2-8.
26. Rebrin K, Steil GM, Getty L, Bergman RN. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 1995, 44:1038-1045. 10.2337/diabetes.44.9.1038, 7657026.
27. Koopmans SJ, Sips HC, Bosman J, Radder JK, Krans HM. Antilipolytic action of insulin in adipocytes from starved and diabetic rats during adenosine-controlled incubations. Endocrinology 1989, 125:3044-3050. 10.1210/endo-125-6-3044, 2684615.
28. Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes 2005, 54:3148-3153. 10.2337/diabetes.54.11.3148, 16249438.
29. Sugden MC, Holness MJ. Potential role of peroxisome proliferator-activated receptor-alpha in the modulation of glucose-stimulated insulin secretion. Diabetes 2004, 53(Suppl 1):S71-S81.
30. Frigerio F, Brun T, Bartley C, Usardi A, Bosco D, Ravnskjaer K, Mandrup S, Maechler P. Peroxisome proliferator-activated receptor alpha (PPARalpha) protects against oleate-induced INS-1E beta cell dysfunction by preserving carbohydrate metabolism. Diabetologia 2010, 53:331-340. 10.1007/s00125-009-1590-6, 19908022.
31. Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis. Diabetes 2008, 57:938-944. 10.2337/db07-0715, 3618659, 18171713.
32. Oslowski CM, Hara T, O'Sullivan-Murphy B, Kanekura K, Lu S, Hara M, Ishigaki S, Zhu LJ, Hayashi E, Hui ST, Greiner D, Kaufman RJ, Bortell R, Urano F. Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome. Cell Metab 2012, 16:265-273. 10.1016/j.cmet.2012.07.005, 22883234.
33. Reich E, Tamary A, Sionov RV, Melloul D. Involvement of thioredoxin-interacting protein (TXNIP) in glucocorticoid-mediated beta cell death. Diabetologia 2012, 55:1048-1057. 10.1007/s00125-011-2422-z, 22246375.
34. Chen J, Fontes G, Saxena G, Poitout V, Shalev A. Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated beta-cell death. Diabetes 2010, 59:440-447. 10.2337/db09-0949, 2809961, 19875615.
35. Rendell M, Stephen PM, Paulsen R, Valentine JL, Rasbold K, Hestorff T, Eastberg S, Shint DC. An interspecies comparison of normal levels of glycosylated hemoglobin and glycosylated albumin. Comp Biochem Physiol B 1985, 81:819-822.
36. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495. 10.2337/diacare.27.6.1487, 15161807.
37. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci USA 1994, 91:10878-10882. 10.1073/pnas.91.23.10878, 45129, 7971976.
38. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998, 47:358-364. 10.2337/diabetes.47.3.358, 9519740.
39. Smith SA, Lister CA, Toseland CD, Buckingham RE. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2000, 2:363-372. 10.1046/j.1463-1326.2000.00099.x, 11225966.
40. Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes 2002, 51:1461-1469. 10.2337/diabetes.51.5.1461, 11978643.